Nexalin Technology

Nexalin Technology

Health Care Equipment & Supplies
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

$118K

Market Cap • 9/28/2026

2010

(16 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,1

P/S

0,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,4

EPS

—

Market Cap

Market Cap

118K

EV

-886,9K

EV/Revenue

-4,1

EV/EBITDA

0,1

EV/EBIT

0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-1201,5%

Total Yield

-1201,5%

Payout

0%

Retained Earnings

-97,2M

Profitability

Gross Margin

86,2%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

627,4%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

1,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

10,2%

CAGR Op. Income 5Y

13,8%

CAGR Net Income 5Y

13,7%

CAGR EPS 5Y

-15,5%

CAGR OCF 5Y

39,4%

Leverage

N.D./EBITDA

0,1

Debt/Equity

0%

Current Ratio

1,1

Quick Ratio

0,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium